A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
← catalyst calendarSponsored by Camurus AB (industry) · CAMX.ST — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
135actual
Sites
68
Countries
Germany, Greece, Hungary +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-10 | actual | When the study began enrolling |
| Primary completion | 2025-04-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-24 | actual | The whole study's end, after follow-up |
| First posted | 2019-10-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acromegaly
Intervention
- Drug: CAM2029 (octreotide subcutaneous depot) — also filed as CAM2029
Primary outcome
what the primary-completion date above is the date OFCharacterization of adverse events (AEs)
measured Week 0-52
Publications
- PMID 40418492 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CAMX.ST's whole pipeline · Catalyst calendar · Every registered study · What changed